Biocomposites acquires bone graft substitute provider Artoss

Biocomposites, a medical device company that engineers, manufactures and markets products to regenerate bone and manage infection in bone and soft tissue, specializes in innovative bone graft alternatives for use in orthopedics, spine, foot and ankle has acquired the manufacturer, Artos. dental care.

Artoss offers a range of bone graft substitute products that utilize its proprietary NanoBone technology – a combination of nanocrystalline hydroxyapatite and silica gel – to provide optimal bone formation with easy handling. The special structure of Nanobone activates the bone-forming forces of the body and heals the bone much faster. In addition to Artoss’ flagship product NanoBone SBX Putty, the company offers a wide range of indication specific product variants that are all ready to use, straight from their applicator.

Based in Rostock, Germany, Artos will continue to develop and manufacture innovative products, but will now be able to serve a larger number of surgeons and patients through access to Biocomposites’ established, global distribution network.

Michael Harris, Chief Executive Officer of Biocomposites, said: “We are delighted to have completed this acquisition of Artoss. The addition of the NanoBone range of products to our portfolio allows us to create a new offering to help surgeons treat their patients and provide a platform to develop new ready-to-use products. Following our acquisitions of Subiton and SineMed last year, we have established ourselves as the go-to provider for surgeons who need bone regeneration and/or need to manage bone and soft tissue infections.